Nephropathy in youth and young adults with type 2 diabetes topical collection on pediatric type 2 diabetes

Current Diabetes Reports

Volumn 14, Issue 2, 2014, Pages

  Solis Herrera, Carolina ^a   Triplitt, Curtis L ^b   Lynch, Jane L ^c  

^a TEXAS TECH UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Microalbuminuria; Nephropathy; Type 2 diabetes; Young adults; Youth

Indexed keywords

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; END STAGE RENAL DISEASE; FATTY LIVER; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; INTENSIVE CARE; JUVENILE; KIDNEY BIOPSY; LIPID BLOOD LEVEL; LOW FAT DIET; MACROALBUMINURIA; MEDICATION COMPLIANCE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PUBERTY; RENOVASCULAR DISEASE; WEIGHT GAIN; YOUNG ADULT; ADOLESCENT; ADULT; FEMALE; KIDNEY DISEASE; MALE; REVIEW;

ADOLESCENT; ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; KIDNEY DISEASES; MALE; YOUNG ADULT;

EID: 84895076629     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0456-y     Document Type: Article

References (100)

1. Alleyn CR, Volkening LK, Wolfson J, et al. Occurrence of microalbuminuria in young people with type 1 diabetes: importance of age and diabetes duration. Diabet Med. 2010;27:532-7. doi: 10.1111/j.1464-5491.2010.02983.x. Comparison of clinical MA occurrence data for children with type 1 and type 2 diabetes in a clinical setting.
2. Eppens MC, Craig ME, Cusumano J, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care. 2006;29:1300-6. doi: 10.2337/dc05-2470.
3. Kiess W, Bottner A, Bluher S, et al. Type 2 diabetes mellitus in children and adolescents - the beginning of a renal catastrophe? Nephrol Dial Transplant. 2004;19:2693-6. doi: 10.1093/ndt/gfh455.
4. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99-111.
5. TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1735-41. doi: 10.2337/dc12-2420. Recent data from the TODAY study cohort specific to the factors associated with early findings of hypertension and MA in youth and young adults with T2D.
6. Marcovecchio ML, Dalton RN, Chiarelli F, et al. A1C variability as an independent risk factor for microalbuminuria in young people with type 1 diabetes. Diabetes Care. 2011;34:1011-3. doi: 10.2337/dc10-2028.
7. Yokoyama H, Okudaira M, Otani T, et al. High incidence of diabetic nephropathy in early-onset Japanese NIDDM patients. Risk analysis. Diabetes Care. 1998;21:1080-5.
8. Rodriguez BL, Dabelea D, Liese AD, et al. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in youth study. J Pediatr. 2010;157:245-251.e1. doi: 10.1016/j.jpeds.2010.02. 021. The characteristics of youth with type 1, type 2 and other forms of diabetes are described in regard to blood pressure observations.
9. Yokoyama H, Okudaira M, Otani T, et al. Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care. 1997;20:844-7.
10. TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and beta-cell function in TODAY. Diabetes Care. 2013;36:1749-57. doi: 10.2337/dc12-2393.
11. D'Adamo E, Caprio S. Type 2 diabetes in youth: Epidemiology and Pathophysiology. Diabetes Care. 2011;34(Suppl 2):S161-5. doi: 10.2337/dc11-s212. Visceral fat accumulation in obese children with a family history of T2D are at risk for accelerated glucose homeostasis dysregulation and β-cell function decline.
12. Amiel SA, Sherwin RS, Simonson DC, et al. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med. 1986;315:215-9. doi: 10.1056/NEJM198607243150402.
13. Barkai L, Vamosi I, Lukacs K. Enhanced progression of urinary albumin excretion in IDDM during puberty. Diabetes Care. 1998;21:1019-23.
14. Amin R, Widmer B, Prevost AT, et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ. 2008;336:697-701. doi: 10.1136/bmj.39478.378241.BE.
15. Pinhas-Hamiel O, Zeitler P. Clinical presentation and treatment of type 2 diabetes in children. Pediatr Diabetes. 2007;8 Suppl 9:16-27. doi: 10.1111/j.1399-5448.2007.00330.x.
16. Linder BL, Fradkin JE, Rodgers GP. The TODAY Study: an NIH perspective on its implications for research. Diabetes Care. 2013;36:1775-6. doi: 10.2337/dc13-0707.
17. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr. 1994;125:177-88.
18. Bryden KS, Dunger DB, Mayou RA, et al. Poor prognosis of young adults with type 1 diabetes: a longitudinal study. Diabetes Care. 2003;26:1052-7.
19. White NH, Cleary PA, Dahms W, et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001;139:804-12.
20. Rosenbloom AL, Silverstein JH, Amemiya S, et al. Type 2 diabetes in children and adolescents. Pediatr Diabetes. 2009;10 Suppl 12:17-32. doi: 10.1111/j.1399-5448.2009.00584.x.
21. SEARCH Study Group. SEARCH for Diabetes in Youth: a multi-center study of the prevalence, incidence and classification of diabetes mellitus in youth. Control Clin Trials. 2004;25:458-71. doi: 10.1016/j.cct.2004.08.002.
22. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693-700. doi: 10.1016/j.jpeds.2004.12.042.
23. Dabelea D, Bell RA, et al. Writing group for the SEARCH for Diabetes in Youth Study Group. Incidence of diabetes in youth in the United States. JAMA. 2007;297:2716-24. doi: 10.1001/jama.297.24.2716.
24. Svensson M, Sundkvist G, Arnqvist HJ, et al. Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care. 2003;26:2903-9.
25. TODAY Study Group, Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247-56. doi: 10.1056/NEJMoa1109333. This is the primary outcome paper describing the significant differences between 3 treatment arms of therapy for newly diagnosed youth with T2D and their comorbidities over an average of 6.5 years in the study.
26. TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1758-64. doi: 10.2337/dc12-2388.
27. Maric-Bilkan C. Obesity and diabetic kidney disease. Med Clin North Am. 2013;97:59-74. doi: 10.1016/j.mcna.2012.10.010.
28. Tsioufis C, Dimitriadis K, Antoniadis D, et al. Inter-relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Am J Hypertens. 2004;17:470-6. doi: 10.1016/j.amjhyper.2004.02.008.
29. Wadwa RP, Urbina EM, Anderson AM, et al. Measures of arterial stiffness in youth with type 1 and type 2 diabetes: the SEARCH for diabetes in youth study. Diabetes Care. 2010;33:881-6. doi: 10.2337/dc09-0747.
30. May AL, Kuklina EV, Yoon PW. Prevalence of cardiovascular disease risk factors among US adolescents, 1999-2008. Pediatrics. 2012;129:1035-41. doi: 10.1542/peds.2011-1082.
31. Peters A, Laffel L, American Diabetes Association Transitions Working Group. Diabetes care for emerging adults: recommendations for transition from pediatric to adult diabetes care systems: a position statement of the American Diabetes Association, with representation by the American College of Osteopathic Family Physicians, the American Academy of Pediatrics, the American Association of Clinical Endocrinologists, the American Osteopathic Association, the Centers for Disease Control and Prevention, Children with Diabetes, The Endocrine Society, the International Society for Pediatric and Adolescent Diabetes, Juvenile Diabetes Research Foundation International, the National Diabetes Education Program, and the Pediatric Endocrine Society (formerly Lawson Wilkins Pediatric Endocrine Society). Diabetes Care. 2011;34:2477-85. doi: 10.2337/dc11-1723. This article discusses the challenges of transition of care when treating the adolescent with T2D.
32. Anderson BJ, Edelstein S, Abramson NW, et al. Depressive symptoms and quality of life in adolescents with type 2 diabetes: baseline data from the TODAY study. Diabetes Care. 2011;34:2205-7. doi: 10.2337/dc11-0431.
33. Nathan DM, Zinman B, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009;169:1307-16.
34. Pambianco G, Costacou T, Ellis D, et al. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes. 2006;55:1463-9.
35. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-86. doi: 10.1056/NEJM199309303291401.
36. DCCT/EDIC Research Group, de Boer IH, Sun W, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366-76. doi: 10.1056/NEJMoa1111732.
37. Maahs DM, Snively BM, Bell RA, et al. Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care. 2007;30:2593-8. doi: 10.2337/dc07-0450.
38. Bogdanovic R. Diabetic nephropathy in children and adolescents. Pediatr Nephrol. 2008;23:507-25. doi: 10.1007/s00467-007-0583-2.
39. Yokoyama H, Okudaira M, Otani T, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 2000;58:302-11. doi: 10.1046/j.1523-1755.2000.00166.x.
40. Eppens MC, Craig ME, Jones TW, et al. Type 2 diabetes in youth from the Western Pacific region: glycaemic control, diabetes care, and complications. Curr Med Res Opin. 2006;22:1013-20. doi: 10.1185/030079906X104795.
41. Kim NH, Pavkov ME, Knowler WC, et al. Predictive value of albuminuria in American Indian youth with or without type 2 diabetes. Pediatrics. 2010;125:e844-51. doi: 10.1542/peds.2009-1230.
42. Pavkov ME, Hanson RL, Knowler WC, et al. Changing patterns of type 2 diabetes incidence among Pima Indians. Diabetes Care. 2007;30:1758-63. doi: 10.2337/dc06-2010.
43. Pavkov ME, Bennett PH, Knowler WC, et al. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA. 2006;296:421-6. doi: 10.1001/jama.296.4. 421.
44. Dart AB, Sellers EA, Martens PJ, et al. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care. 2012;35:1265-71. doi: 10.2337/dc11-2312. ICD code based review of 1353 youth with diabetes and a control group to determine the long term renovascular outcomes in first nation Canadian youth. These T2D youths had a 23-fold increased risk for renal failure and a 39-fold increased risk for dialysis when compared with control subjects and a 4-fold increase in renal failure compared with T1D youth.
45. Dean H. NIDDM-Y in First Nation children in Canada. Clin Pediatr. 1998;37:89-96.
46. Sellers EA, Blydt-Hansen TD, Dean HJ, et al. Macroalbuminuria and renal pathology in First Nation youth with type 2 diabetes. Diabetes Care. 2009;32:786-90. doi: 10.2337/dc08-1828.
47. Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35:2061-8. doi: 10.2337/dc11-2189.
48. Tsioufis C, Mazaraki A, Dimitriadis K, et al. Microalbuminuria in the paediatric age: current knowledge and emerging questions. Acta Paediatr. 2011;100:1180-4. doi: 10.1111/j.1651-2227.2011.02291.x.
49. Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet. 2007;369:1823-31. doi: 10.1016/S0140-6736(07)60821-6.
50. Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care. 2003;26:2999-3005.
51. Ettinger LM, Freeman K, DiMartino-Nardi JR, et al. Microalbuminuria and abnormal ambulatory blood pressure in adolescents with type 2 diabetes mellitus. J Pediatr. 2005;147:67-73. doi: 10.1016/j.jpeds.2005.02.003.
52. Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96:159-67. doi: 10.1210/jc.2010-1642.
53. Savino A, Pelliccia P, Chiarelli F, et al. Obesity-related renal injury in childhood. Horm Res Paediatr. 2010;73:303-11. doi: 10.1159/000308161. This article review the association between obesity and the risk of kidney disease with regard to childhood.
54. Ritz E, Koleganova N, Piecha G. Is there an obesity-metabolic syndrome related glomerulopathy? Curr Opin Nephrol Hypertens. 2011;20:44-9. doi: 10.1097/MNH.0b013e3283414ca1. There is evidence for a focal segmental glomerosclerosis related to obesity as well as a likely aggravation of most primary kidney disease in the obese patient.
55. Burgert TS, Dziura J, Yeckel C, et al. Microalbuminuria in pediatric obesity: prevalence and relation to other cardiovascular risk factors. Int J Obes. 2006;30:273-80. doi: 10.1038/sj.ijo.0803136.
56. Schultz CJ, Konopelska-Bahu T, Dalton RN, et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care. 1999;22:495-502.
57. Olsen BS, Sjolie AK, Hougaard P, et al. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications. 2004;18:160-4. doi: 10.1016/S1056-8727(03)00073-4.
58. Doublier S, Lupia E, Catanuto P, et al. Estrogens and progression of diabetic kidney damage. Curr Diabetes Rev. 2011;7:28-34.
59. Bangstad HJ, Dahl-Jorgensen K, Kjaersgaard P, et al. Urinary albumin excretion rate and puberty in non-diabetic children and adolescents. Acta Paediatr. 1993;82:857-62.
60. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med. 2008;25 Suppl 2:25-9. doi: 10.1111/j.1464-5491.2008.02496.x.
61. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72. doi: 10.1056/NEJMoa0802987.
62. Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 2012;172:761-9. doi: 10.1001/archinternmed.2011.2230.
63. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA. 2013. Published online December 18, 2013. doi: 10.1001/jama.2013.284427. This evidence-based document provides an updated analysis of current evidence regarding BP treatment thresholds, goals, and drug treatment strategies focused on date for adults above age 18 years of age.
64. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-8. doi: 10.1001/jama.2010.884.
65. Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med. 2010;123:719-26. doi: 10.1016/j.amjmed.2010.02.014.
66. Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005;16:2170-9. doi: 10.1681/ASN.2004090763.
67. Rhodes ET, Prosser LA, Hoerger TJ, et al. Estimated morbidity and mortality in adolescents and young adults diagnosed with type 2 diabetes mellitus. Diabet Med. 2012;29:453-63. doi: 10.1111/j.1464-5491.2011.03542.x.
68. Yusuf S, Teo KK, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
69. Hermida RC, Ayala DE, Mojon A, et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011;22:2313-21. doi: 10.1681/ASN.2011040361.
70. Urbina EM, Kimball TR, Khoury PR, et al. Increased arterial stiffness is found in adolescents with obesity or obesity-related type 2 diabetes mellitus. J Hypertens. 2010;28:1692-8. doi: 10.1097/HJH.0b013e32833a6132.
71. Song SH, Hardisty CA. Early onset type 2 diabetes mellitus: a harbinger for complications in later years - clinical observation from a secondary care cohort. QJM. 2009;102:799-806. doi: 10.1093/qjmed/hcp121.
72. Wu AY, Kong NC, de Leon FA, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia. 2005;48:17-26. doi: 10.1007/s00125-004- 1599-9.
73. Toto RD. Lessons from the African-American Study of kidney disease and hypertension: an update. Curr Hypertens Rep. 2006;8:409-12.
74. Wright Jr JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-31.
75. Rahman M, Douglas JG, Wright Jr JT. Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab Clin North Am. 1997;26:125-44.
76. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91. doi: 10.1056/NEJMoa0706245.
77. Copeland KC, Silverstein J, Moore KR, et al. Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and adolescents. Pediatrics. 2013;131:364-82. doi: 10.1542/peds.2012-3494. Clinical practice guideline for evidence based care for youth and young adults with type 2 Diabetes. This guideline underwent peer review and is endorsed by the Academy of Pediatrics.
78. Dart AB, Sellers EA, Dean HJ. Kidney disease and youth onset type 2 diabetes: considerations for the general practitioner. Int J Pediatr. 2012;2012:237360. doi: 10.1155/2012/237360. Practical clinical advice for management of renovascular complications in youth onset T2D.
79. Davis CL. Undetected hypertension and prehypertension in children with diabetes need attention. J Pediatr. 2010;157:182-4. doi: 10.1016/j.jpeds.2010. 04.022.
80. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA. 2007;298:874-9. doi: 10.1001/jama.298.8.874.
81. Flynn J. The changing face of pediatric hypertension in the era of the childhood obesity epidemic. Pediatr Nephrol. 2013;28:1059-66. doi: 10.1007/s00467-012-2344-0.
82. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-76.
83. Bell DS. Hypertension and diabetes: a toxic combination. Endocr Pract. 2008;14:1031-9.
84. Bakris G, Vassalotti J, Ritz E, et al. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int. 2010;78:726-36. doi: 10.1038/ki.2010.292.
85. Springer SC, Silverstein J, Copeland K, et al. Management of type 2 diabetes mellitus in children and adolescents. Pediatrics. 2013;131:e648-64. doi: 10.1542/peds.2012-3496.
86. Parving HH, Smidt UM, Hommel E, et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis. 1993;22:188-95.
87. Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55:1832-9.
88. Marcovecchio ML, Tossavainen PH, Dunger DB. Status and rationale of renoprotection studies in adolescents with type 1 diabetes. Pediatr Diabetes. 2009;10:347-55. doi: 10.1111/j.1399-5448.2009.00510.x.
89. Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285-93. doi: 10.1056/NEJMoa021835.
90. Salardi S, Balsamo C, Zucchini S, et al. High rate of regression from micro-macroalbuminuria to normoalbuminuria in children and adolescents with type 1 diabetes treated or not with enalapril: the influence of HDL cholesterol. Diabetes Care. 2011;34:424-9. doi: 10.2337/dc10-1177.
91. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225-32. doi: 10.1046/j.1523-1755.2003.00712.x.
92. Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164-76.
93. Hill JO, Galloway JM, Goley A, et al. Scientific statement: socioecological determinants of prediabetes and type 2 diabetes. Diabetes Care. 2013. doi: 10.2337/dc13-1161.
94. Kawahara R, Amemiya T, Yoshino M, et al. Dropout of young non-insulin-dependent diabetics from diabetic care. Diabetes Res Clin Pract. 1994;24:181-5.
95. de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001;63:619-30.
96. Le-Ha C, Beilin LJ, Burrows S, et al. Oral contraceptive use in girls and alcohol consumption in boys are associated with increased blood pressure in late adolescence. Eur J Prev Cardiol. 2012. doi: 10.1177/2047487312452966.
97. Nielsen LR, Damm P, Mathiesen ER. Improved pregnancy outcome in type 1 diabetic women with microalbuminuria or diabetic nephropathy: effect of intensified antihypertensive therapy? Diabetes Care. 2009;32:38-44. doi: 10.2337/dc08-1526.
98. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443-51. doi: 10.1056/NEJMoa055202.
99. Young EC, Pires ML, Marques LP, et al. Effects of pregnancy on the onset and progression of diabetic nephropathy and of diabetic nephropathy on pregnancy outcomes. Diabetes Metab Syndr. 2011;5:137-42. doi: 10.1016/j.dsx.2012.02.013.
100. Mathiesen ER, Ringholm L, Feldt-Rasmussen B, et al. Obstetric nephrology: pregnancy in women with diabetic nephropathy - the role of antihypertensive treatment. Clin J Am Soc Nephrol. 2012;7:2081-8. doi: 10.2215/CJN.00920112.